Comparison of Tc-99m Sestamibi and F-18FDG-PET in the assessment of multiple myeloma

被引:0
作者
Hung, GU
Tsai, CC
Tsai, SC
Lin, WY
机构
[1] Taichung Vet Gen Hosp, Dept Nucl Med, Sect 3, Taichung 407, Taiwan
[2] Changhua Christian Hosp, Dept Nucl Med, Changhua, Taiwan
[3] Tainan Municipal Hosp, Dept Radiol, Tainan, Taiwan
[4] Show Chwan Mem Hosp, Changhua, Taiwan
关键词
FDG-PET; MIBI scan; multiple myeloma; bone marrow involvement; soft tissue lesions; skeletal lesions;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Tc-99m inethoxy-isobutyl-isonitrile (MIBI) has been reported to be a useful tracer in patients with multiple myeloma (MM). Few articles have reported the potential value of fluorine-18 fluorodeoxyglucose positron emission toniography (FDG-PET) in the evaluation of MM. Therefore, the purpose of this study was to compare the diagnostic abilities of the MIBI scan and the FDG-PET scan in the evaluation of MM Materials and Methods: Twelve patients with MM were included. All patients received a radiological skeletal survey, MIBI scan and FDG-PET scan. Results: Thirty-four lesions (19 soft tissue lesions and 15 skeletal lesions) plus 5 cases of bone marrow involvement were detected. The conventional skeletal X-ray survey detected 4 soft tissue lesions (27.1%), 12 skeletal lesions (80%), but no bone marrow involvement (0%). The MIBI scan found 4 cases of bone marrow involvement (80%), 13 soft tissue lesions (68.4%) and 12 skeletal lesions (80%). The PET scan detected 5 cases of bone marrow involvement (100%), 17 soft tissue lesions (89.5%) and 74 skeletal lesions (93.3%). Conclusion: Both the MIBI and the FDG-PET scans are useful in the evaluation of patients with MM. However, FDG-PET can detect more lesions than the MIBI scan in patients with MM.
引用
收藏
页码:4737 / 4741
页数:5
相关论文
共 27 条
[1]  
Adams BK, 1996, J NUCL MED, V37, P1001
[2]  
Alexandrakis MG, 2001, ANN HEMATOL, V80, P349
[3]  
Balleari E, 2001, HAEMATOLOGICA, V86, P78
[4]   TC-99(M)-SESTAMIBI AS AN AGENT FOR IMAGING P-GLYCOPROTEIN-MEDIATED MULTIDRUG-RESISTANCE - IN-VITRO AND IN-VIVO STUDIES IN A RAT BREAST-TUMOR CELL-LINE AND ITS DOXORUBICIN-RESISTANT VARIANT [J].
BALLINGER, JR ;
HUA, HA ;
BERRY, BW ;
FIRBY, P ;
BOXEN, I .
NUCLEAR MEDICINE COMMUNICATIONS, 1995, 16 (04) :253-257
[5]   Detection of lymphoma in bone marrow by whole-body positron emission tomography [J].
Carr, R ;
Barrington, SF ;
Madan, B ;
O'Doherty, MJ ;
Saunders, CAB ;
van der Walt, J ;
Timothy, AR .
BLOOD, 1998, 91 (09) :3340-3346
[6]  
CARVALHO PA, 1992, J NUCL MED, V33, P1516
[7]  
Catalano L, 1999, HAEMATOLOGICA, V84, P119
[8]  
CHIU ML, 1990, J NUCL MED, V31, P1646
[9]   MRI IN THE DETECTION OF MALIGNANT INFILTRATION OF BONE-MARROW [J].
DAFFNER, RH ;
LUPETIN, AR ;
DASH, N ;
DEEB, ZL ;
SEFCZEK, RJ ;
SCHAPIRO, RL .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1986, 146 (02) :353-358
[10]  
DELMONMOINGEON LI, 1990, CANCER RES, V50, P2198